Jacqueline Ameri,


Co-founder & CEO 

Dr. Ameri has spearheaded the research development, financing, commercialization aspects of the project since 2014 and serves as co-founder and CEO. As co-inventor of the company’s technology she has dedicated the last decade of her career to develop strategies for differentiating human pluripotent stem cells (hPSCs) towards endoderm and pancreatic cell lineages. In parallel, Dr. Ameri works as Assistant Professor at the Novo Nordisk Foundation Center for Stem Cell Biology (DanStem) at the Faculty of Health and Medical Sciences, University of Copenhagen. During the period 2015-2017 she was also working as Project Manager for the Diabetes Cell Therapy program initiated in the Section for Strategic Translational Stem Cell Research and Therapy (TransStem) at DanStem.

In 2015, Dr. Ameri was awarded a pre-seed grant (~2.5M DKK) from Novo Seeds (Novo Nordisk Foundation) and in 2016 she received a proof of concept grant (0.5M DKK) from the University of Copenhagen for her project “Developing methods for expandable production of hPSC-derived insulin-producing beta cells for cell therapy in diabetes” and to support the establishment of Pancryos. In October 2017, a second tranche of 1M DKK was awarded by the Novo Nordisk Foundation through Novo Seeds to support the continuation of the pre-seed project Pancryos and importantly to complete initial in vivo proof of concepts studies with implanted hES-derived β-cells generated through the optimised Pancryos differentiation protocol. Dr. Ameri’s recent advances in establishing a streamlined strategy, for generation of mature insulin producing cells together with the identification of novel cell surface markers for isolation of beta cell progenitors, put her in reach of achieving the long-sought goal of her career; offering stem cell therapy to diabetes patients.

Henrik Semb,


Co-founder, Scientific Advisor

Professor Semb is a renowned professor of Stem Cell Biology and Developmental Biology of the Pancreas. His research has during the past 15+ years focused on elucidating basic mechanism in morphogenesis and cell differentiation during organogenesis using a combination of in vivo and in vitro genetic and cell biological experimental tools. In parallel, Professor Semb is the Executive Director of the Novo Nordisk Foundation Center For Stem Cell Biology. Danstem is funded by the Novo Nordisk Foundation for a 10-year period. Professor Semb’s scientific achievements in the field of pancreas development and beta cell biology have been recognized by many international and national grant-awarding bodies throughout his research career, including; the EU, EMBO, Swedish Foundation for Strategic Research, the Swedish Government, the US National Institute of Health (NIH) and the Juvenile Diabetes Research Foundation.

Professor Semb holds several patents and has previously acted as a co-founder and scientific advisor for the Gothenburg based company Cellartis AB that commercialized various human ES cell applications. Cellartis was purchased by Cellectis in 2011, and subsequently bought by Takara bio inc. in 2014.


Raphael Scharfmann,



Research Director at INSERM Cochin Institute in Paris, France

Dr. Scharfmann’ research group focus on understanding pancreatic endocrine cell development and particularly the insulin-producing beta cells. The major objective of his research for the past 15 years has been to elucidate the intercellular signals regulating beta cell development and his lab has developed in vitro bioassays using rodent fetal pancreas to screen for signals that regulate pancreatic progenitor cell proliferation and differentiation into beta cells. In parallel, they are developing innovative assays to transfer data generated in rodent models to human. Dr Sharfmann has received several awards for his exceptional work in the field of Diabetes research in Europe including the prestigious Minkowski Award 1999, the European Society for Clinical Investigation award in 2003, the French National Academy of Medicine award in 2010, and the Bettencourt Award in 2012.

Per-Ola Carlsson,



Professor in Medical Cell Biology at Uppsala University, Sweden.

In addition to his professorship at Uppsala University, professor Carlsson serves as senior endocrinologist at the Division for Diabetology and Endocrinology at Uppsala University Hospital, and is a member of the board of the Nordic Network for Clinical Islet Transplantation. Professor Carlsson has received several awards for his exceptional work in T1D research, including the Rising Star Award by the European Association for the Study of Diabetes in 2005, the Fernstrom Award in 2010, and the Swedish Juvenile Diabetes Foundation Prize in 2012. Professor Carlsson’s research focus has been on islet vascular biology, islet oxygenation, and engraftment of transplanted pancreatic islets, on intervention studies to prevent development of overt T1D in newly diagnosed T1D patients, non-invasive imaging of human islet mass, as well as on clinical islet transplantation studies. Currently, Professor Carlsson serves as the principal investigator in phase I and IIa clinical trials conducted by the device company Beta-O2 Technologies, Ltd.


Mads E. Matthiesen


Co-founder and CEO at CathVision ApS

Mr Matthiesen is a serial entrepreneur who has co-founded several companies in the medtech/biotech area (Antag Therapeutics, FindZebra, CathVision, BioRepeller) and has vast experience in corporate and strategic planning and financing and is currently serving as CEO at CathVision. Mr Matthiesen holds a Masters in Medical Engineering from Technical University of Denmark. He has previously also worked as management consultant at The Boston Consulting Group.  


Hans T. Schambye


Co-founder and CEO at Galecto Biotech

Dr. Schambye is a serial entrepreneur who has co-founded several biotech companies and have extensive background in corporate strategy, financing and management, drug discovery and development and is currently serving as CEO at Galecto Biotech. Dr. Schambye holds an MD from Odense University and a PhD in Molecular Pharmacology from Copenhagen University. In his previous positions, Dr. Schambye served as the CEO of ReceptIcon, Gastrotech Pharma A/S and as Director of Biology and Pharmacology and Head of Portfolio Management at the US based biotech company Maxygen.

Hilde H. Steineger


Co-founder & COO at NorthSea Therapeutics and CEO of Staten Biotechnology

Dr Steineger is a former financial analyst, venture capitalist and head of business development within the life science industry. She also serves on the Board of Directors of PCI Biotech Holding, Nordic Nanovector and Strongbridge BioPharma.


Anders Mørkeberg Hinsby


CEO of Orphazyme

Dr Hinsby is a biotech entrepreneur who has previously worked as a biotech venture capital investor at BankInvest Biomedical Venture.  In 2017 he brought Orphazyme to IPO on Nasdaq Copenhagen, raising 80M€ in one of the most successful IPOs for Biotech in Europe.

Sveinung Hole


CEO at Bergen Research Foundation

Mr Hole has 15 years of board and leadership experience from the healthcare sector and is currently CEO of the Bergen Research Foundation and the Stiftelsen Kristian Gerhard Jebsen foundation.